Results 11 to 20 of about 1,395,710 (388)
Lymphoma immunophenotyping: “borderline” lymphomas [PDF]
Journal of Cellular and Molecular Medicine, 2000 AbstractImmunophenotyping of B‐cell lymphoproliferative disorders is indispensable, especially in disorders with CD19(+) CD5(+) B lymphocytes, where we have to make the distinction between low grade neoplasia, such as chronic lymphocytic leukemia with CD23(+) malignant lymphocytes, and aggressive neoplasia such as mantle cell lymphoma with CD23 ...
Nicoleta Olteanu +7 more
openaire +3 more sources
Diffuse Large B-Cell Lymphoma.
New England Journal of Medicine, 2021 Large B-cell lymphomas, with an estimated 150,000 new cases annually worldwide, represent almost 30% of all cases of non-Hodgkin’s lymphoma. Patients typically present with progressive lymphadenopathy, extranodal disease, or both and require therapy ...
L. Sehn, G. Salles
semanticscholar +1 more source
KTE-X19 CAR T-Cell Therapy in Relapsed or Refractory Mantle-Cell Lymphoma.
New England Journal of Medicine, 2020 BACKGROUND Patients with relapsed or refractory mantle-cell lymphoma who have disease progression during or after the receipt of Bruton's tyrosine kinase (BTK) inhibitor therapy have a poor prognosis. KTE-X19, an anti-CD19 chimeric antigen receptor (CAR)
Michael L. Wang +24 more
semanticscholar +1 more source
New England Journal of Medicine, 2002 Background The standard treatment for patients with diffuse large-B-cell lymphoma is cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP). Rituximab, a chimeric monoclonal antibody against the CD20 B-cell antigen, has therapeutic activity in
B. E. C. Oiffier +12 more
semanticscholar +2 more sources
Cancers, 2021 Vitreoretinal lymphoma (VRL) is a rare variant of primary central nervous system lymphoma (PCNSL), mostly of diffuse large B cell lymphoma, which affects the retina and/or the vitreous with or without optic nerve involvement. The disease course is aggressive. Up to 90% of the patients develop central nervous system lymphoma within one year.
Bianka Sobolewska +7 more
openaire +2 more sources
Journal of Clinical Oncology, 2014 The purpose of this work was to modernize recommendations for evaluation, staging, and response assessment of patients with Hodgkin lymphoma (HL) and non-Hodgkin lymphoma (NHL).
B. Cheson +6 more
semanticscholar +1 more source
Tisagenlecleucel in Adult Relapsed or Refractory Diffuse Large B‐Cell Lymphoma
New England Journal of Medicine, 2019 BACKGROUND Patients with diffuse large B‐cell lymphoma that is refractory to primary and second‐line therapies or that has relapsed after stem‐cell transplantation have a poor prognosis. The chimeric antigen receptor (CAR) T‐cell therapy tisagenlecleucel
S. Schuster +23 more
semanticscholar +1 more source
Incidental Lymphoplasmacytic Lymphoma Diagnosed Following Robotic-Assisted Laparoscopic Prostatectomy for Prostate Cancer [PDF]
, 2019 © 2019 The Author(s). This article is licensed under the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License (CC BY-NC-ND).
Agarwal, Samita +5 more
core +2 more sources
New England Journal of Medicine, 2002 BACKGROUND The survival of patients with diffuse large-B-cell lymphoma after chemotherapy is influenced by molecular features of the tumors. We used the gene-expression profiles of these lymphomas to develop a molecular predictor of survival.
A. Rosenwald +39 more
semanticscholar +1 more source
Anaplastic lymphoma kinase inhibition in non-small-cell lung cancer.
New England Journal of Medicine, 2010 BACKGROUND Oncogenic fusion genes consisting of EML4 and anaplastic lymphoma kinase (ALK) are present in a subgroup of non-small-cell lung cancers, representing 2 to 7% of such tumors. We explored the therapeutic efficacy of inhibiting ALK in such tumors
E. Kwak +33 more
semanticscholar +1 more source